{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:04:08Z","timestamp":1789621448799,"version":"build-2803163510"},"reference-count":15,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Managing patients on antiplatelet (AP) therapy undergoing transurethral resection of bladder cancer (TURBT) is challenging due to bleeding and thromboembolic risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients who underwent TURBT between January 2020 and December 2024. Patients were divided into an AP group and a control group without AP therapy. Demographic, perioperative, and postoperative parameters, including low-molecular-weight heparin (LMWH) bridging, were evaluated. The primary endpoint was readmission due to hematuria within 30\u2009days; secondary outcomes included rehospitalization, clot retention, and reoperation. Logistic regression analyses identified predictors of readmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 103 patients were included, with 40 in the AP group and 63 in the control group. Readmission with hematuria occurred in 10% of AP patients versus 6.3% of controls (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.707). All readmissions in the AP group involved clopidogrel users, alone or with acetylsalicylic acid (ASA), while none occurred in ASA-only users (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.004). Rehospitalization was observed only in the AP group (7.5% vs 0%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.055). LMWH bridging (OR\u2009=\u200918.40, 95%CI\u2009=\u20092.93\u2013115.40,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.002) and clopidogrel use (OR\u2009=\u200910.88, 95%\u2009CI\u2009=\u20092.2851.94,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.003) predicted readmission in univariable analysis but not multivariable models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Perioperative ASA monotherapy appears safe, while clopidogrel use may increase the risk of hematuria-related readmission and warrants closer monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03915603261430487","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:33:42Z","timestamp":1774121622000},"page":"370-375","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hematuria-related readmission after transurethral resection of bladder tumor in patients receiving antiplatelet therapy"],"prefix":"10.1177","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0599-5436","authenticated-orcid":false,"given":"Abdullah","family":"Ilktac","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Department of Urology, Bezmialem Vakif University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-8525","authenticated-orcid":false,"given":"Bayram","family":"Dogan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Urology, Bezmialem Vakif University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3717-7080","authenticated-orcid":false,"given":"Fatih","family":"Gevher","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Urology, Bezmialem Vakif University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffer","family":"Akcay","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Urology, Bezmialem Vakif University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Akbulut","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Urology, Bezmialem Vakif University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1483-9160","authenticated-orcid":false,"given":"Yusuf O.","family":"Ilbey","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Urology, Bezmialem Vakif University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","unstructured":"Bray F Laversanne M Sung H et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"Comp\u00e9rat E Larr\u00e9 S Roupret M et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch 2015; 466: 589\u2013594. https:\/\/doi.org\/10.1007\/s00428-015-1739-2","DOI":"10.1007\/s00428-015-1739-2"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","unstructured":"Wu F Wu S Huang Y et al. Smoking promotes the progression of bladder cancer through FOXM1\/CKAP2L axis. J Transl Med 2025; 23: 785. https:\/\/doi.org\/10.1186\/s12967-025-06835-2","DOI":"10.1186\/s12967-025-06835-2"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","unstructured":"Kim LHC Patel MI. Transurethral resection of bladder tumour (TURBT). Transl Androl Urol 2020; 9: 3056\u20133072. https:\/\/doi.org\/10.21037\/tau.2019.09.38","DOI":"10.21037\/tau.2019.09.38"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","unstructured":"Rambachan A Matulewicz RS Pilecki M et al. Predictors of readmission following outpatient urological surgery. J Urol 2014; 192: 183\u2013188. https:\/\/doi.org\/10.1016\/j.juro.2013.12.053","DOI":"10.1016\/j.juro.2013.12.053"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","unstructured":"Pereira JF Pareek G Mueller-Leonhard C et al. The perioperative morbidity of transurethral resection of bladder tumor: implications for Quality Improvement. Urology 2019; 125: 131\u2013137. https:\/\/doi.org\/10.1016\/j.urology.2018.10.027","DOI":"10.1016\/j.urology.2018.10.027"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"Laferri\u00e8re C Moazzami C Belley-C\u00f4t\u00e9 E et al. Aspirin for the primary prevention of vascular ischemic events: an updated systematic review and meta-analysis to support shared decision-making. CJC open 2023; 5: 881\u2013890. https:\/\/doi.org\/10.1016\/j.cjco.2023.08.011","DOI":"10.1016\/j.cjco.2023.08.011"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","unstructured":"Hollenbeck BK Miller DC Taub D et al. Risk factors for adverse outcomes after transurethral resection of bladder tumors. Cancer 2006; 106: 1527\u20131535. https:\/\/doi.org\/10.1002\/cncr.21765","DOI":"10.1002\/cncr.21765"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","unstructured":"Pellegrino P Scherer TP Wettstein MS et al. Development of a nomogram for prediction of postoperative bleeding after transurethral resection of bladder tumors. Int Urol Nephrol 2026; 58: 921\u2013929. https:\/\/doi.org\/10.1007\/s11255-025-04734-5","DOI":"10.1007\/s11255-025-04734-5"},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","unstructured":"Jindal T Sarwal A Jain P et al. A retrospective analysis of the factors associated with increased risk of readmission within 30 days after primary transurethral resection of bladder tumor. Curr Urol 2023; 17: 257\u2013261. https:\/\/doi.org\/10.1097\/CU9.0000000000000160","DOI":"10.1097\/CU9.0000000000000160"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"Picozzi S Marenghi C Ricci C et al. Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease. Surg Endosc 2014; 28: 116\u2013121. https:\/\/doi.org\/10.1007\/s00464-013-3136-8","DOI":"10.1007\/s00464-013-3136-8"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Scherer TP Dam C Bieri U et al. Risk of postoperative bleeding and thromboembolic events in anticoagulated patients undergoing transurethral resection of bladder tumors. Ther Adv Urol 2025; 17: 17562872251315930. https:\/\/doi.org\/10.1177\/17562872251315930","DOI":"10.1177\/17562872251315930"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","unstructured":"Konishi T Washino S Nakamura Y et al. Risks and complications of transurethral resection of bladder tumors in patients receiving antiplatelet and\/or anticoagulant therapy: a retrospective cohort study. BMC Urol 2017; 17: 118. https:\/\/doi.org\/10.1186\/s12894-017-0309-0","DOI":"10.1186\/s12894-017-0309-0"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","unstructured":"Prader R De Broca B Chevallier D et al. Outcome of transurethral resection of bladder tumor: does antiplatelet therapy really matter? Analysis of a retrospective series. J Endourol 2017; 31: 1284\u20131288. https:\/\/doi.org\/10.1089\/end.2017.0587","DOI":"10.1089\/end.2017.0587"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","unstructured":"Ragonese M Fettucciari D Carbone L et al. Predictive factors for major complications and urological cancer diagnosis in older adults (\u2a7e80 years) admitted to the Emergency Department for Hematuria. J Clin Med 2024; 13: 2874. https:\/\/doi.org\/10.3390\/jcm13102874","DOI":"10.3390\/jcm13102874"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261430487","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603261430487","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261430487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:36:25Z","timestamp":1789619785000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603261430487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/03915603261430487"],"URL":"https:\/\/doi.org\/10.1177\/03915603261430487","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]}}}